Comparative in vitro activity of cefpirome (HR 810) against gram-positive isolates from cancer patients.
The activity of cefpirome against gram-positive isolates from cancer patients was compared to that of currently available extended-spectrum cephalosporins. Cefpirome was active against methicillin-susceptible, coagulase-positive, and coagulase-negative staphylococci. It was the most active agent against streptococci belonging to Lancefield groups A, B and G and Streptococcus pneumoniae. 76% of enterococcal isolates were susceptible to cefpirome - far more than any of the other agents tested.